{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:35:01Z","timestamp":1787002501717,"version":"build-2736575974"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/ncpendmet0069","type":"journal-article","created":{"date-parts":[[2006,5,16]],"date-time":"2006-05-16T13:03:16Z","timestamp":1147784596000},"page":"32-41","source":"Crossref","is-referenced-by-count":48,"title":["Drug Insight: recent advances in male hormonal contraception"],"prefix":"10.1038","volume":"2","author":[{"given":"John K","family":"Amory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie T","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Bremner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpendmet0069_CR1","unstructured":"Anonymous (1999) Notice to readers: world's population to reach six billion. Morb Mortal Wkly Rep 48: 859"},{"key":"BFncpendmet0069_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2307\/2991522","volume":"30","author":"SK Henshaw","year":"1998","unstructured":"Henshaw SK (1998) Unintended pregnancy in the US. Fam Plann Perspect 30: 24\u201329","journal-title":"Fam Plann Perspect"},{"key":"BFncpendmet0069_CR3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/jurban\/jth122","volume":"81","author":"M Besculides","year":"2004","unstructured":"Besculides M and Laraque F (2004) Unintended pregnancy among the urban poor. J Urban Health 81: 340\u2013348","journal-title":"J Urban Health"},{"key":"BFncpendmet0069_CR4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2307\/2991517","volume":"30","author":"LJ Piccinino","year":"1998","unstructured":"Piccinino LJ and Mosher WD (1998) Trends in contraceptive use in the United States: 1982\u20131995. Fam Plan Perspect 30: 4\u201310","journal-title":"Fam Plan Perspect"},{"key":"BFncpendmet0069_CR5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/humrep\/15.3.637","volume":"15","author":"CW Martin","year":"2000","unstructured":"Martin CW et al. (2000) Potential impact of hormonal male contraception: cross-cultural implications for development of novel male preparations. Human Reprod 15: 637\u2013645","journal-title":"Human Reprod"},{"key":"BFncpendmet0069_CR6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/humrep\/deh574","volume":"20","author":"K Heinemann","year":"2005","unstructured":"Heinemann K et al. (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20: 549\u2013556","journal-title":"Hum Reprod"},{"key":"BFncpendmet0069_CR7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/humrep\/15.3.646","volume":"15","author":"AF Glasier","year":"2000","unstructured":"Glasier AF et al. (2000) Would women trust their partners to use a male pill? Human Reprod 15: 646\u2013649","journal-title":"Human Reprod"},{"key":"BFncpendmet0069_CR8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3181\/00379727-40-10527P","volume":"40","author":"MJ Heckel","year":"1939","unstructured":"Heckel MJ (1939) Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 40: 658\u2013659","journal-title":"Proc Soc Exp Biol Med"},{"key":"BFncpendmet0069_CR9","doi-asserted-by":"crossref","unstructured":"World Health Organization Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336: 995\u2013999","DOI":"10.1016\/0140-6736(90)92416-F"},{"key":"BFncpendmet0069_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0015-0282(16)57307-5","volume":"63","author":"DJ Handelsman","year":"1995","unstructured":"Handelsman DJ et al. (1995) Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil Steril 63: 125\u2013133","journal-title":"Fertil Steril"},{"key":"BFncpendmet0069_CR11","doi-asserted-by":"crossref","unstructured":"World Health Organization Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65: 821\u2013829","DOI":"10.1016\/S0015-0282(16)58221-1"},{"key":"BFncpendmet0069_CR12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1210\/jc.2002-020447","volume":"88","author":"Y-Q Gu","year":"2003","unstructured":"Gu Y-Q et al. (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88: 562\u2013568","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR13","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1210\/jc.2003-030107","volume":"88","author":"L Turner","year":"2003","unstructured":"Turner L et al. (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88: 4659\u20134667","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR14","first-page":"375","volume":"25","author":"E Nieschlag","year":"2003","unstructured":"Nieschlag E et al. (2003) Sixth summit meeting consensus: recommendations for regulatory approval for hormonal male contraception. Int J Androl 25: 375","journal-title":"Int J Androl"},{"key":"BFncpendmet0069_CR15","first-page":"561","volume":"79","author":"CJ Bagatell","year":"1994","unstructured":"Bagatell CJ et al. (1994) Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 79: 561\u2013567","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ijan.1995.18.5.237","volume":"18","author":"MC Meriggiola","year":"1995","unstructured":"Meriggiola MC et al. (1995) Testosterone enanthate at the dose 200 mg\/week decreases HDL-cholesterol levels in healthy men. Int J Androl 18: 237\u2013242","journal-title":"Int J Androl"},{"key":"BFncpendmet0069_CR17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/j.1939-4640.2002.tb02272.x","volume":"23","author":"M Zitzmann","year":"2002","unstructured":"Zitzmann M et al. (2002) Contraceptive steroids influence the hemostatic activation state in healthy men. J Androl 23: 503\u2013511","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0010-7824(01)00223-2","volume":"64","author":"B Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren B and Gottlieb C (2001) Testosterone for male contraception during one year: attitudes, well-being and quality of sex life. Contraception 64: 59\u201365","journal-title":"Contraception"},{"key":"BFncpendmet0069_CR19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2307\/2136111","volume":"27","author":"K Ringheim","year":"1995","unstructured":"Ringheim K (1995) Evidence for the acceptability of an injectable hormonal method for men. Fam Plann Perspect 27: 123\u2013128","journal-title":"Fam Plann Perspect"},{"key":"BFncpendmet0069_CR20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1530\/acta.0.0790789","volume":"79","author":"A Coert","year":"1975","unstructured":"Coert A et al. (1975) The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol (Copenh) 79: 789\u2013800","journal-title":"Acta Endocrinol (Copenh)"},{"key":"BFncpendmet0069_CR21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/j.1939-4640.1998.tb02086.x","volume":"19","author":"GY Zhang","year":"1998","unstructured":"Zhang GY et al. (1998) A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 19: 761\u2013768","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1530\/eje.0.1400414","volume":"140","author":"AM Behre","year":"1999","unstructured":"Behre AM et al. (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endrocrinol 140: 414\u2013419","journal-title":"Eur J Endrocrinol"},{"key":"BFncpendmet0069_CR23","first-page":"3642","volume":"84","author":"GY Zhang","year":"1999","unstructured":"Zhang GY et al. (1999) Injectable testosterone undecanoate for contraception in Chinese men. J Clin Endocrinol Metab 84: 3642\u20133647","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2265.2000.01024.x","volume":"53","author":"A Kamischke","year":"2000","unstructured":"Kamischke A et al. (2000) Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clinical Endocrinol 53: 43\u201352","journal-title":"Clinical Endocrinol"},{"key":"BFncpendmet0069_CR25","first-page":"303","volume":"86","author":"A Kamischke","year":"2001","unstructured":"Kamischke A et al. (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86: 303\u2013309","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/eje.1.01878","volume":"152","author":"A Junaidi","year":"2005","unstructured":"Junaidi A et al. (2005) Norethisterone enanthate has neither a direct effect on the testis nor on the epididymis: a study in adult male cynomolgus monkeys (Macaca fascicularis). Eur J Endocrinol 152: 655\u2013661","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0069_CR27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2605.1978.tb00517.x","volume":"2","author":"SB Schearer","year":"1978","unstructured":"Schearer SB et al. (1978) Hormonal contraception for men. Int J Androl 2: 680\u2013695","journal-title":"Int J Androl"},{"key":"BFncpendmet0069_CR28","first-page":"113","volume":"17","author":"K Fotherby","year":"1972","unstructured":"Fotherby K et al. (1972) Effect of low doses of synthetic progestagens on testicular function. Int J Fertil 17: 113\u2013119","journal-title":"Int J Fertil"},{"key":"BFncpendmet0069_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0010-7824(79)90084-2","volume":"20","author":"A Barfield","year":"1977","unstructured":"Barfield A et al. (1977) Pregnancies associated with sperm concentrations below 10 million\/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 20: 121\u2013127","journal-title":"Contraception"},{"key":"BFncpendmet0069_CR30","first-page":"757","volume":"81","author":"RA Bebb","year":"1996","unstructured":"Bebb RA et al. (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81: 757\u2013762","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/j.1939-4640.1999.tb02535.x","volume":"20","author":"BD Anawalt","year":"1999","unstructured":"Anawalt BD et al. (1999) A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 20: 407\u2013414","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2164\/jandrol.04135","volume":"26","author":"BD Anawalt","year":"2005","unstructured":"Anawalt BD et al. (2005) Very low-dosage oral levonorgestrel plus intramuscular testosterone enanthate suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl 26: 405\u2013413","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/j.1939-4640.2004.tb02846.x","volume":"25","author":"YL Gui","year":"2004","unstructured":"Gui YL et al. (2004) Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl 25: 720\u2013727","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR34","first-page":"112","volume":"84","author":"FC Wu","year":"1999","unstructured":"Wu FC et al. (1999) Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary\u2013testicular axis, and lipid metabolism. J Clin Endocrinol Metab 84: 112\u2013122","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0015-0282(00)01490-4","volume":"74","author":"BD Anawalt","year":"2000","unstructured":"Anawalt BD et al. (2000) Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril 74: 707\u2013714","journal-title":"Fertil Steril"},{"key":"BFncpendmet0069_CR36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/17.6.1490","volume":"17","author":"D Kinniburgh","year":"2002","unstructured":"Kinniburgh D et al. (2002) Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 17: 1490\u20131501","journal-title":"Hum Reprod"},{"key":"BFncpendmet0069_CR37","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/humrep\/17.11.2869","volume":"17","author":"RA Anderson","year":"2002","unstructured":"Anderson RA et al. (2002) Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum Reprod 17: 2869\u20132877","journal-title":"Hum Reprod"},{"key":"BFncpendmet0069_CR38","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2004-0895","volume":"90","author":"CJ Hay","year":"2005","unstructured":"Hay CJ et al. (2005) A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J Clin Endocrinol Metab 90: 2042\u20132049","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR39","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1210\/jcem.87.8.8773","volume":"87","author":"RA Anderson","year":"2002","unstructured":"Anderson RA et al. (2002) Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 87: 3640\u20133649","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR40","unstructured":"Brady DM et al. A multi-centre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod, in press"},{"key":"BFncpendmet0069_CR41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0022-4731(86)90320-1","volume":"25","author":"F Neumann","year":"1986","unstructured":"Neumann F and Topert M (1986) Pharmacology of antiandrogens. J Steroid Biochem 25: 885\u2013895","journal-title":"J Steroid Biochem"},{"key":"BFncpendmet0069_CR42","first-page":"3018","volume":"81","author":"MC Meriggiola","year":"1996","unstructured":"Meriggiola MC et al. (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 81: 3018\u20133023","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR43","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/humrep\/13.5.1225","volume":"13","author":"MC Meriggiola","year":"1998","unstructured":"Meriggiola MC et al. (1998) Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod 13: 1225\u20131229","journal-title":"Hum Reprod"},{"key":"BFncpendmet0069_CR44","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0015-0282(97)00363-4","volume":"68","author":"MC Meriggiola","year":"1997","unstructured":"Meriggiola MC et al. (1997) An oral regimen of cyproterone acetate and testosterone for spermatogenic suppression in men. Fertil Steril 68: 844\u2013850","journal-title":"Fertil Steril"},{"key":"BFncpendmet0069_CR45","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1210\/jcem.87.5.8514","volume":"87","author":"MC Meriggiola","year":"2002","unstructured":"Meriggiola MC et al. (2002) Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab 87: 2107\u20132113","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2265.2000.01097.x","volume":"53","author":"A Kamischke","year":"2000","unstructured":"Kamischke A et al. (2000) Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin Endocrinol (Oxf) 53: 351\u2013358","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFncpendmet0069_CR47","first-page":"303","volume":"86","author":"A Kamischke","year":"2001","unstructured":"Kamischke A et al. (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86: 303\u2013309","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR48","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1210\/jc.2004-1852","volume":"90","author":"MC Meriggiola","year":"2005","unstructured":"Meriggiola MC et al. (2005) Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals of spermatogenesis, reproductive hormones, testis and prostate. J Clin Endocrinol Metab 90: 2005\u20132014","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1210\/jcem.87.2.8218","volume":"87","author":"A Kamischke","year":"2002","unstructured":"Kamischke A et al. (2002) An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 87: 530\u2013539","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR50","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1210\/jc.2003-031307","volume":"89","author":"YQ Gu","year":"2004","unstructured":"Gu YQ et al. (2004) Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J Clin Endocrinol Metab 89: 2254\u20132262","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR51","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jcem-73-6-1360","volume":"73","author":"SN Pavlou","year":"1991","unstructured":"Pavlou SN et al. (1991) Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 73: 1360\u20131369","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR52","first-page":"476","volume":"75","author":"L Tom","year":"1992","unstructured":"Tom L et al. (1992) Induction of azoospermia in normal men with combined Nal\u2013Glu gonadotropin-releasing hormone and testosterone enanthate. J Clin Endocrinol Metab 75: 476\u2013483","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR53","first-page":"427","volume":"77","author":"CJ Bagatell","year":"1993","unstructured":"Bagatell CJ et al. (1993) Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 77: 427\u2013432","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR54","first-page":"3527","volume":"83","author":"RS Swerdloff","year":"1998","unstructured":"Swerdloff RS et al. (1998) Suppression of spermatogenesis in man induced by Nal\u2013Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab 83: 3527\u20133533","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR55","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/humrep\/16.12.2570","volume":"16","author":"HM Behre","year":"2001","unstructured":"Behre HM et al. (2001) Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 16: 2570\u20132577","journal-title":"Hum Reprod"},{"key":"BFncpendmet0069_CR56","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0022-5347(05)66353-7","volume":"165","author":"K Tomera","year":"2001","unstructured":"Tomera K et al. (2001) The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165: 1585\u20131589","journal-title":"J Urol"},{"key":"BFncpendmet0069_CR57","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1210\/jc.2003-032123","volume":"89","author":"KL Herbst","year":"2004","unstructured":"Herbst KL et al. (2004) Acyline, a gonadotropin releasing-hormone antagonist suppresses gonadotropins and testosterone for 15 days after a single dose. J Clin Endocrinol Metab 89: 5959\u20135965","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jc.2004-1228","volume":"90","author":"KL Matthiesson","year":"2005","unstructured":"Matthiesson KL et al. (2005) Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5-\u03b1-reductase inhibitor or GnRH antagonist. J Clin Endocrinol Metab 90: 91\u201397","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR59","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1021\/jm9803673","volume":"41","author":"N Cho","year":"1998","unstructured":"Cho N et al. (1998) Discovery of a novel, potent and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem 41: 4190\u20134195","journal-title":"J Med Chem"},{"key":"BFncpendmet0069_CR60","first-page":"1244","volume":"84","author":"D Buchter","year":"1999","unstructured":"Buchter D et al. (1999) Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 84: 1244\u20131249","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR61","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1210\/jcem.86.11.8028","volume":"86","author":"WM Hair","year":"2001","unstructured":"Hair WM et al. (2001) A novel male contraceptive pill\u2013patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab 86: 5201\u20135209","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR62","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1210\/jcem.87.8.8710","volume":"87","author":"IT Gonzalo","year":"2002","unstructured":"Gonzalo IT et al. (2002) Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87: 3562\u20133572","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2605.1988.tb00994.x","volume":"11","author":"JF Guerin","year":"1988","unstructured":"Guerin JF and Rollet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11: 187\u2013199","journal-title":"Int J Androl"},{"key":"BFncpendmet0069_CR64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2605.2001.00319.x","volume":"24","author":"P Pollanen","year":"2001","unstructured":"Pollanen P et al. (2001) Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl 24: 369\u2013380","journal-title":"Int J Androl"},{"key":"BFncpendmet0069_CR65","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2002-021058","volume":"88","author":"C Steidle","year":"2003","unstructured":"Steidle C et al. (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88: 2673\u20132681","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR66","first-page":"222","volume":"2","author":"J Rosen","year":"2002","unstructured":"Rosen J and Negro-Vilar A (2002) Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact 2: 222\u2013224","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"BFncpendmet0069_CR67","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1124\/jpet.104.075424","volume":"213","author":"J Chen","year":"2005","unstructured":"Chen J et al. (2005) A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther 213: 546\u2013553","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncpendmet0069_CR68","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1210\/jc.2004-1221","volume":"90","author":"JK Amory","year":"2005","unstructured":"Amory JK and Bremner WJ (2005) Oral testosterone in oil plus dutasteride: a pharmacokinetic study in men. J Clin Endocrinol Metab 90: 2610\u20132617","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR69","first-page":"290","volume":"77","author":"EM Wallace","year":"1993","unstructured":"Wallace EM et al. (1993) Comparison between testosterone enanthate-induced azoospermia and oligoazoospermia in a male contraceptive study I: plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol and inhibin concentrations. J Clin Endocrinol Metab 77: 290\u2013293","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR70","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/j.1939-4640.2001.tb03445.x","volume":"22","author":"JK Amory","year":"2001","unstructured":"Amory JK et al. (2001) Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development. J Androl 2001 22: 1053\u20131060","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR71","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1210\/jc.2003-030616","volume":"89","author":"RI McLachlan","year":"2004","unstructured":"McLachlan RI et al. (2004) Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 89: 142\u2013149","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR72","first-page":"902","volume":"81","author":"RA Anderson","year":"1996","unstructured":"Anderson RA et al. (1996) Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5\u03b1-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 81: 902\u2013908","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR73","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1210\/jcem.87.2.8231","volume":"87","author":"RI McLachlan","year":"2002","unstructured":"McLachlan RI et al. (2002) Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab 87: 546\u2013556","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0010-7824(00)00139-6","volume":"62","author":"RI McLachlan","year":"2000","unstructured":"McLachlan RI et al. (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5\u03b1-reductase inhibitor, for male hormonal contraception. Contraception 62: 73\u201378","journal-title":"Contraception"},{"key":"BFncpendmet0069_CR75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/j.1939-4640.2001.tb02157.x","volume":"22","author":"D Kinniburgh","year":"2001","unstructured":"Kinniburgh D et al. (2001) Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl 22: 88\u201395","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR76","doi-asserted-by":"crossref","first-page":"13692","DOI":"10.1073\/pnas.2232815100","volume":"100","author":"FP Zhang","year":"2003","unstructured":"Zhang FP et al. (2003) The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc Natl Acad Sci USA 100: 13692\u201313697","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpendmet0069_CR77","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/j.1939-4640.2002.tb02311.x","volume":"23","author":"MC Meriggiola","year":"2002","unstructured":"Meriggiola MC et al. (2002) Higher testosterone dose impairs sperm suppression induced by a combined androgen\u2013progestin regimen. J Androl 23: 684\u2013690","journal-title":"J Androl"},{"key":"BFncpendmet0069_CR78","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1210\/jcem.86.9.7793","volume":"86","author":"B Yu","year":"2001","unstructured":"Yu B and Handelsman DJ (2001) Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J Clin Endocrinol Metab 86: 4406\u20134411","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0069_CR79","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2265.2002.01652.x","volume":"57","author":"Eckardstein","year":"2002","unstructured":"Eckardstein et al. (2002) CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 57: 647\u2013655","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0069","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpendmet0069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T07:22:44Z","timestamp":1707031364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BFncpendmet0069"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0069","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}